Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
4(80.0%)
N/A
1(20.0%)
5Total
Phase 2(4)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04341181Phase 2Recruiting

ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling

Role: lead

NCT03890952Phase 2Completed

Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma

Role: lead

NCT02290522Not ApplicableUnknown

Copenhagen Prospective Personalized Oncology (CoPPO)

Role: lead

NCT01251484Phase 2Completed

BIBF 1120 in Recurrent Glioblastoma Multiforme

Role: lead

NCT00817284Phase 2Completed

Bevacizumab and Irinotecan or Bevacizumab and Temozolomide With Concomitant Radiotherapy for Primary Glioblastoma Multiforme (GBM)

Role: lead

All 5 trials loaded